PTY vs. IBB, HTGC, DNP, ADX, USA, NUV, GSBD, GAB, RVT, and TY
Should you be buying PIMCO Corporate & Income Opportunity Fund stock or one of its competitors? The main competitors of PIMCO Corporate & Income Opportunity Fund include iShares Biotechnology ETF (IBB), Hercules Capital (HTGC), DNP Select Income Fund (DNP), Adams Diversified Equity Fund (ADX), Liberty All-Star Equity Fund (USA), Nuveen Municipal Value Fund (NUV), Goldman Sachs BDC (GSBD), The Gabelli Equity Trust (GAB), Royce Value Trust (RVT), and Tri-Continental (TY). These companies are all part of the "investment offices, not elsewhere classified" industry.
iShares Biotechnology ETF (NASDAQ:IBB) and PIMCO Corporate & Income Opportunity Fund (NYSE:PTY) are both mid-cap finance companies, but which is the better investment? We will contrast the two companies based on the strength of their community ranking, analyst recommendations, risk, institutional ownership, profitability, earnings, dividends, media sentiment and valuation.
62.5% of iShares Biotechnology ETF shares are held by institutional investors. Comparatively, 10.3% of PIMCO Corporate & Income Opportunity Fund shares are held by institutional investors. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
iShares Biotechnology ETF has a beta of 0.75, meaning that its share price is 25% less volatile than the S&P 500. Comparatively, PIMCO Corporate & Income Opportunity Fund has a beta of 0.97, meaning that its share price is 3% less volatile than the S&P 500.
Given PIMCO Corporate & Income Opportunity Fund's higher possible upside, research analysts clearly believe iShares Biotechnology ETF is more favorable than PIMCO Corporate & Income Opportunity Fund.
iShares Biotechnology ETF pays an annual dividend of $0.41 per share and has a dividend yield of 0.3%. PIMCO Corporate & Income Opportunity Fund pays an annual dividend of $1.43 per share and has a dividend yield of 10.0%.
iShares Biotechnology ETF received 35 more outperform votes than PIMCO Corporate & Income Opportunity Fund when rated by MarketBeat users. Likewise, 67.09% of users gave iShares Biotechnology ETF an outperform vote while only 64.92% of users gave PIMCO Corporate & Income Opportunity Fund an outperform vote.
In the previous week, iShares Biotechnology ETF had 5 more articles in the media than PIMCO Corporate & Income Opportunity Fund. MarketBeat recorded 6 mentions for iShares Biotechnology ETF and 1 mentions for PIMCO Corporate & Income Opportunity Fund. PIMCO Corporate & Income Opportunity Fund's average media sentiment score of 0.90 beat iShares Biotechnology ETF's score of -1.00 indicating that iShares Biotechnology ETF is being referred to more favorably in the media.
Summary
iShares Biotechnology ETF beats PIMCO Corporate & Income Opportunity Fund on 7 of the 9 factors compared between the two stocks.
Get PIMCO Corporate & Income Opportunity Fund News Delivered to You Automatically
Sign up to receive the latest news and ratings for PTY and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PTY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
PIMCO Corporate & Income Opportunity Fund Competitors List
Related Companies and Tools
